The Association for Molecular Pathology (AMP) on Tuesday announced that it has published a report to assess clinical adoption, identify classification inconsistencies, and evaluate implementation barriers for the 2017 report, “Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.”
The AMP manuscript, “Assessments of Somatic Variant Classification Using the AMP/ASCO/CAP Guidelines,” was released online ahead of publication in The Journal of Molecular Diagnostics.
The 2017 guidelines were developed by a panel of experts to help standardize the interpretation and reporting of sequence variants in cancer. They were based on evidence from a comprehensive review of published literature, empirical data, current laboratory practice surveys, feedback from multiple public meetings, and professional experiences.
The report proposed a four-tiered system to categorize somatic sequence variations based on their clinical significance in cancer diagnosis, prognosis, and/or therapeutics:
- Tier 1: Variants with strong clinical significance
- Tier 2: Variants with potential clinical significance
- Tier 3: Variants of unknown clinical significance
- Tier 4: Variants deemed benign or likely benign
In 2018, the AMP Variant Interpretation Across Testing Laboratories (VITAL) Somatic Working Group was formed to better understand the implementation and utilization of the previous guidelines among laboratories, assess concordance between laboratories, and identify content within the guidelines that may result in variant classification inconsistencies between laboratories. The project involved VITAL Somatic Challenges and an implementation survey.
“Cancer genomics is a rapidly evolving field, and the increasing use of NGS technologies has raised new challenges, especially regarding how somatic variants are interpreted and how molecular results are reported by different clinical laboratories,” Jane Gibson, 2022 AMP clinical practice committee chair, said in a statement. “As part of our ongoing commitment to improving clinical practice, AMP will continue to reassess and modify our guidelines as needed to address common challenges and improve patient care.”
The VITAL Somatic Challenges demonstrated that 86% of participants correctly differentiated clinically significant variants from variants of uncertain significance and benign/likely benign variants; more than 70% of participants agreed in judging the potential for germline variants.
Meanwhile, the survey showed that 71% of respondents implemented the guidelines for variant classification, and more than 90% of them utilized the recommended tier-based reporting system.
According to AMP, the project identified several areas for improvement, including a more granular and comprehensive classification system, more detailed guidelines on interpretation and reporting, and additional educational programs for clinical laboratory professionals and medical oncologists.
AMP added that it will continue to collaborate with key stakeholders in the cancer genomics community and will use the results obtained from these studies to help inform future revisions of guidelines.